In the BioHarmony Drug Report Database

"Preview" Icon

Ibrexafungerp

Brexafemme (ibrexafungerp) is a small molecule pharmaceutical. Ibrexafungerp was first approved as Brexafemme on 2021-06-01. It is used to treat vulvovaginal candidiasis in the USA. Brexafemme’s patents are valid until 2035-01-19 (FDA).

 

Trade Name

 

Brexafemme
 

Common Name

 

ibrexafungerp
 

ChEMBL ID

 

CHEMBL4297513
 

Indication

 

vulvovaginal candidiasis
 

Drug Class

 

Antifungal

Image (chem structure or protein)

Ibrexafungerp structure rendering